From: optimalFlow: optimal transport approach to flow cytometry gating and population matching
Center | Final diagnosis | Tested sample | Coagulant | Sex | Age | Incubation period | Flow cytometer | |
---|---|---|---|---|---|---|---|---|
\({\mathcal {C}}^{1}\) | 1 | HD | PB | EDTA | M | 53 | 30 | BD FACSCanto |
\({\mathcal {C}}^{2}\) | 1 | HD | PB | EDTA | M | 50 | 30 | BD FACSCanto |
\({\mathcal {C}}^{3}\) | 1 | HD | PB | EDTA | M | 61 | 30 | BD FACSCanto |
\({\mathcal {C}}^{4}\) | 2 | HD | PB | Heparin | M | 29 | 30 | BD FACSCanto |
\({\mathcal {C}}^{5}\) | 2 | HD | PB | Heparin | M | 38 | 30 | BD FACSCanto |
\({\mathcal {C}}^{6}\) | 2 | HD | PB | Heparin | F | 27 | 30 | BD FACSCanto |
\({\mathcal {C}}^{7}\) | 2 | HD | PB | Heparin | F | NA | 30 | BD FACSCanto |
\({\mathcal {C}}^{8}\) | 2 | HD | PB | Heparin | M | NA | 30 | BD FACSCanto |
\({\mathcal {C}}^{9}\) | 2 | HD | PB | Heparin | F | NA | 30 | BD FACSCanto |
\({\mathcal {C}}^{10}\) | 2 | HD | PB | Heparin | F | NA | 30 | BD FACSCanto |
\({\mathcal {C}}^{11}\) | 3 | HD | PB | NA | M | 34 | 15 | BD FACSCanto |
\({\mathcal {C}}^{12}\) | 3 | HD | PB | NA | F | 33 | 15 | BD FACSCanto |
\({\mathcal {C}}^{13}\) | 3 | HD | PB | NA | M | 32 | 15 | BD FACSCanto |
\({\mathcal {C}}^{14}\) | 3 | HD | PB | NA | M | 33 | 15 | BD FACSCanto |
\({\mathcal {C}}^{15}\) | 3 | HD | PB | NA | F | 35 | 15 | BD FACSCanto |
\({\mathcal {C}}^{16}\) | 3 | HD | PB | EDTA | NA | Adult | 15 | BD FACSCanto |
\({\mathcal {C}}^{17}\) | 3 | HD | PB | EDTA | NA | Adult | 15 | BD FACSCanto |
\({\mathcal {C}}^{18}\) | 3 | HD | PB | EDTA | NA | Adult | 15 | BD FACSCanto |
\({\mathcal {C}}^{19}\) | 3 | HD | PB | EDTA | NA | Adult | 15 | BD FACSCanto |
\({\mathcal {C}}^{20}\) | 3 | HD | PB | EDTA | NA | Adult | 15 | BD FACSCanto |
\({\mathcal {C}}^{21}\) | NA | HD | NA | NA | NA | NA | NA | BD FACSCanto |
\({\mathcal {C}}^{22}\) | 4 | MCL | PB | NA | F | 82 | 15 | BD FACSCanto |
\({\mathcal {C}}^{23}\) | 4 | MCL | PB | NA | M | 70 | 15 | BD FACSCanto |
\({\mathcal {C}}^{24}\) | 4 | FL | BM | NA | M | 52 | 15 | BD FACSCanto |
\({\mathcal {C}}^{25}\) | 4 | MCL | BM | NA | M | 81 | 15 | BD FACSCanto |
\({\mathcal {C}}^{26}\) | 4 | LPL | PB | NA | M | 67 | 15 | BD FACSCanto |
\({\mathcal {C}}^{27}\) | 1 | CLL | LN | Other | F | 61 | 30 | BD FACSCanto |
\({\mathcal {C}}^{28}\) | 1 | CLL | LN | Other | F | 61 | 30 | BD FACSCanto |
\({\mathcal {C}}^{29}\) | 1 | HD | PB | EDTA | F | 27 | 30 | BD FACSCanto |
\({\mathcal {C}}^{30}\) | 1 | HD | PB | EDTA | M | 54 | 30 | BD FACSCanto |
\({\mathcal {C}}^{31}\) | 1 | HD | PB | EDTA | M | 50 | 30 | BD FACSCanto |
\({\mathcal {C}}^{32}\) | 1 | HD | PB | EDTA | F | 36 | 30 | BD FACSCanto |
\({\mathcal {C}}^{33}\) | 1 | HD | PB | EDTA | M | 74 | 30 | BD FACSCanto |
\({\mathcal {C}}^{34}\) | 1 | DLBCL | Other | Other | M | 65 | 30 | BD FACSCanto |
\({\mathcal {C}}^{35}\) | 1 | HCL | BM | EDTA | M | 40 | 30 | BD FACSCanto |
\({\mathcal {C}}^{36}\) | 2 | HD | PB | Heparin | M | 38 | 30 | BD FACSCanto |
\({\mathcal {C}}^{37}\) | 2 | HD | PB | Heparin | F | 27 | 30 | BD FACSCanto |
\({\mathcal {C}}^{38}\) | 2 | HD | PB | Heparin | M | NA | 30 | BD FACSCanto |
\({\mathcal {C}}^{39}\) | 2 | HD | PB | Heparin | F | NA | 30 | BD FACSCanto |
\({\mathcal {C}}^{40}\) | 3 | HD | PB | EDTA | NA | NA | 15 | BD FACSCanto |